Effective on June 1, 2017, Bioventus' full surgical orthobiologics portfolio was made available through premier.
Here are three takeaways:
1. Bioventus Surgical has numerous offerings for bone healing and spine fusion including allograft bone, synthetic bone graft substitutes and cell and marrow extraction needles.
2. There are eight new products in the expanded portfolio.
3. Senior Vice President Henry Tung, MD, said, "The Bioventus Surgical portfolio is designed to meet the needs of surgeons and their patients across a broad range of clinical situations, procedures and costs."